This column is my opinion and expresses my views. Those views can change at a moments notice when the market changes. I am not right all the time and I do not expect to be. I disclose all my positions clearly listed on the page, and I do not trade my account on the stocks spoken of in this column unless fully disclosed. If that does not work for you stop reading and close the page. Do not bother me or harass me.
Otherwise, enjoy the column!
Subscribe to the Monster Stock Market Commentary and join the 2,366 subscribers getting it for FREE every day!
June 17, 2020
STOCKS – NFLX, FB, ORCL, BABA
MACRO – SPY, XBI
Mike Reading The Markets Premium Content – $35/Month or $300/Year
- For Live Webinar On 6/18
- Trying To Break Free – Midday
- Big Break Set To Happen Today
- Just Fillin’ Gaps Or Something More?
- Uber May See A Steep Decline
- Stocks Are Set To Sink – Morning
- A Massive Week Lies Ahead For The Stock Market
S&P 500 (SPY)
It turned out to be a pretty wild day, not all that different then what I expected. The S&P 500 index finished the day nearly 90 basis points off its highs, to close the day down by 36 basis points. Something is going on at the 3140 level in the S&P 500, which is acting as a firm-level of resistance during the last two days. Perhaps it has something to do with options expiration on Friday, but it seems the buyers tried mightly to break that level a handful of times and have been unsuccessful. By the day’s end, it just seemed like the buyers were outnumbered and overwhelmed, and the market drifted lower.
Volume levels in the SPY have been drifting lower since Tuesday morning, a sign that the number of buyers was thinning. Meanwhile, volume accelerated on the late-day decline, suggesting sellers took over. I would not rule out a pullback tomorrow to $306 on the SPY.
(Excluding ext. hours)
Even the downtrend I pointed yesterday is still enforced, with the SPY failing right at it early today.
(including ext. hours)
Tomorrow will, of course, be, initial and continuing jobless claims. At this point, the continuing claims appear to be the more important number to follow, as it gives a better sense of how many people are returning to work. In the last three weeks, we have been stuck around 21 million. Should claims rise above that level, it would not be viewed as a positive by the markets, as it would suggest that not many people are returning to work. A drop below 20 million would likely be considered to be positive and play into the reopening is going great trade.
Netflix has a pattern that looks awfully like a head and shoulders. It also has a declining volume pattern from left to right and an RSI that is trending lower. All a telltale sign of that pattern. So I think this is important for two reasons, one that the stock potentially goes significantly lower. Two, because it seems it is very much a bullish sentiment trade.
Alibaba has been steadily trending higher, and I noticed some bullish betting in it this morning. For now, the first level of resistance comes at $232. You can read more in this free article I wrote- Alibaba’s Advance Is Likely To Push On
Facebook got pinned down at $237.50 today, and as I noted yesterday, I think this one goes lower, potentially back to $203.
Oracle managed to hold on to support in that $51-52 region. That is a significant support level.
Biotech ETF (XBI)
It looks someone doesn’t want the XBI rising above $105.50. The RSI is trending lower. Therefore a move lower for the ETF may be coming soon. I’d watch that $105.50 level very carefully.
Have a good one
Mott Capital Management, LLC is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and, unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Past performance is not indicative of future results.